Medscape: Analysis boosts Fluvoxamine for COVID, but what's the evidence?
UC expert says research may be useful, but more trials are needed
A report published recently in JAMA Open Network finds there's a strong likelihood that the antidepressant fluvoxamine (Luvox) may moderately lower rates of hospitalization due to COVID-19 in unvaccinated patients. However, outside experts cited by Medscape differ over whether the evidence from just three studies is strong enough to warrant adding the drug to the COVID-19 treatment arsenal. One of those experts sources is Carl Fichtenbaum, MD, of the Division of Infectious Diseases at the UC College of Medicine.
Carl Fichtenbaum, MD, of the Division of Infectious Diseases at the UC College of Medicine/Photo/Joe Fuqua II/UC Creative + Brand
"This research might be valuable, but the jury remains out until several other adequately powered and designed trials are completed," said Fichtenbaum, who's familiar with the findings. "I'm not sure how useful this is given we have several antiviral agents available. Why would we choose this over Paxlovid, remdesivir, or molnupiravir?"
According to Fichtenbaum, researchers began focusing on fluvoxamine after case reports about patients improving while on the medication. This led to further interest, he said, boosted by the drug's known ability to dampen the immune system.
Lead photo/Science News
Next Lives Here
The University of Cincinnati is classified as a Research 1 institution by the Carnegie Commission and is ranked in the National Science Foundation's Top-35 public research universities. UC's medical, graduate and undergraduate students and faculty investigate problems and innovate solutions with real-world impact. Next Lives Here.
Related Stories
‘GangTok’: Study provides insights about the presence of gang culture on Tiktok
May 12, 2026
John Leverso, an assistant professor in the UC School of Criminal Justice, is lead author of the research, 'GangTok: Street gang content, culture, and roleplay on TikTok' published recently in Crime, Media, Culture: An International Journal.
Is there anything to fear from Hantavirus?
May 12, 2026
The University of Cincinnati's Carl Fichtenbaum, MD, professor of clinical medicine in the Division of Infectious Diseases in the Department of Internal Medicine at the College of Medicine, recently appeared on Scott Sloan's show on 700 WLW to share facts surrounding Hantavirus.
College of Medicine alumnae and faculty chair support shared alma mater
May 12, 2026
Michael A. Thomas, MD,[MS1.1] and Cincinnati OB-GYN Megan Kessler, MD, Med ’92 met in the hallways of the University of Cincinnati College of Medicine in the early 1990s.